Pyrimidine Depletion Enhances Targeted and Immune Therapy Combinations in Acute Myeloid Leukemia

Researchers introduced HOSU-53, a dihydroorotate dehydrogenase inhibitor with significant monotherapy activity, which was further enhanced when combined with other standard-of-care therapeutics.